Genetic Signatures' Sales Drop in Fiscal Q3
Genetic Signatures (ASX:GSS) logged sales of AU$1.7 million for the third quarter of fiscal 2024, down from AU$2 million in the year-ago period, according to an April 26 filing with the Australian bou
Genetic Technologies Raises US$2 Million as It Eyes Global Expansion | ASX:GTG, NASDAQ:GENE, OTC:GNTLF
Investors in Integral Diagnostics (ASX:IDX) Have Unfortunately Lost 40% Over the Last Three Years
Rhythm Biosciences Appoints CEO; Shares Down 3%
Rhythm Biosciences (ASX:RHY) appointed David Atkins as chief executive, effective May 13. Atkins has experience across a broad range of life sciences and healthcare disciplines, according to a Wednesd
Microba's Revenue Climbs 297% in Fiscal Q3
Microba Life Sciences' (ASX:MAP) revenue surged 297% year-on-year to AU$4 million in the third fiscal quarter as the medical diagnostics company launched its world-first pathogen test, according to a
These ASX Dividend Winners Keep Giving Investors a Pay Rise
Some ASX dividend shares have been growing their dividend payouts over many years, which is impressive considering the challenges facing the share market in recent times.